Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887.HK) has experienced a significant decline in stock price since its debut on the Hong Kong Stock Exchange, reflecting poor financial performance and market sentiment [1] Financial Performance - Dongyang Sunshine Pharmaceutical's stock closed at HKD 49.00, down 4.39%, marking five consecutive days of decline, with an intraday low of HKD 48.36, the lowest since its listing [1] - The company reported a 37% year-on-year decline in revenue for 2024, with operating profit down 78.4% and net profit down 97.55% [1] - Revenue figures for 2022, 2023, and 2024 were CNY 3.814 billion, CNY 6.386 billion, and CNY 4.019 billion respectively, with gross profit of CNY 2.922 billion, CNY 5.077 billion, and CNY 3.059 billion [1] - Operating profits for the same years were CNY -793 million, CNY 1.766 billion, and CNY 381 million, while net profits were CNY -1.416 billion, CNY 1.014 billion, and CNY 24.8 million [1] Market Reaction - On its first trading day, Dongyang Sunshine Pharmaceutical's stock closed at HKD 59.90, up 4.17%, with an intraday high of HKD 62.30, reflecting an 8.35% increase [1]